Jump to content

Property:Outcome specification

From CAMIH

This is a property of type Text.

Showing 20 pages using this property.
T
Baseline + every 2 months (for 3 years), then every 4 months (up to the 5th year), then twice a year  +
Baseline; T1-T3 (Day 2 post surgery - Day 4 post surgery, follow-up) Value; coefficient of the time x group interaction effect βI (standard error),p-value  +
U
Scintigraphic parameters: Uptake fraction (UF); Uptake index (UI), Excretion fraction (EF), Excretion ratio (ER))  +
5-year overall survival = elapsed time from the date of randomization (ie, time from starting the study medication to the date of death due to any cause), as well as incidence of relapse, cancer- specific death, and noncancer death  +
Relapse-free survival = elapsed time from the date of randomization (ie, time from starting the study medication to the earliest date of cancer relapse or death due to any cause)  +
Severity of nausea at T1 (acute) and T2 (delayed) (0-10, 0 = none, 10 = strongest possible nausea) Nausea was defined a disorder characterized by a queasy sensation and/or the urge to vomit  +
Degree of nausea Grade 0 defined as normal appetite; Grade 1 defined as loss of appetite without alteration in eating habits; Grade 2 defined as decreased oral intake without significant weight loss, dehydration, or malnutrition; Grade 3 defined as inadequate oral caloric or fluid intake  +
Frequency of vomiting Vomiting was defined a disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.  +
QoL with EORTC QLQ C30: Functional Scale, Symptom Scale, Global Health Scale (week 1,3,5 chemotherapy)  +
Adverse effects with CTCAE: pain, fatigue, nausea, vomiting, diarrhea, constipation, flatulence, urinary urgency and proctitis (week 1-5 of chemotherapy)  +
V